Search clinical trials for: linaclotide or placebo

Total 58517 results

Ironwood Pharmaceuticals, Inc.
Forest Laboratories

Completed

Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Irritable Bowel Syndrome With Constipation

United States
Texas Tech University Health Sciences Center, El...

Active, not recruiting

Efficacy of Linaclotide in Type II Diabetics With Chronic Constipation

Diabete Mellitus | Chronic Constipation

United States
Forest Laboratories
Ironwood Pharmaceuticals, Inc.

Completed

Safety and Efficacy of Linaclotide in Patients With Chronic Constipation and Prominent Abdominal Bloating

Constipation | Chronic Constipation

United States, Canada
Forest Laboratories
Ironwood Pharmaceuticals, Inc.

Terminated

A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With Constipation (LIN-MD-63)

Irritable Bowel Syndrome With Constipation

United States, Canada
AbbVie
Ironwood Pharmaceuticals, Inc.

Active, not recruiting

Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC) (LINZESS)

Irritable Bowel Syndrome With Constipation | Functional Constipation

United States, Belgium, Bulgaria, Canada, Estonia, Israel, Italy, Netherlands, Poland, Puerto Rico, Spain, Ukraine, United Kingdom, Germany
Forest Laboratories
Ironwood Pharmaceuticals, Inc.

Completed

Phase III, Randomized, Double-Blind, Placebo-Controlled, Trial of Linaclotide Administered to Patients With Chronic Constipation

Chronic Constipation

United States, Canada
Forest Laboratories
Ironwood Pharmaceuticals, Inc.

Completed

Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain

Opioid-Induced Constipation

United States
Astellas Pharma Inc

Completed

A Study of Oral Dosing of ASP0456 in Patients With Chronic Constipation

Chronic Constipation

Japan
Astellas Pharma Inc

Completed

Phase III Study to Evaluate the Efficacy and Safety of ASP0456 in Patients With Constipation Predominant Irritable Bowel Syndrome

Irritable Bowel Syndrome With Constipation (IBS-C)

Japan
Ironwood Pharmaceuticals, Inc.

Completed

Randomized, Double-blind, Dose-range-finding, Phase 2 Study of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Irritable Bowel Syndrome With Constipation

United States, Canada
Astellas Pharma Inc

Completed

A Study to Evaluate Safety of Multiple Dose of ASP0456 in Healthy Subjects

Healthy | Pharmacokinetics of ASP0456

Japan
Astellas Pharma Inc

Completed

A Safety and Pharmacokinetics Study of ASP0456 in Healthy Subjects

Healthy | Pharmacokinetics of ASP0456

Japan
AbbVie
Ironwood Pharmaceuticals, Inc.

Recruiting

A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation

Functional Constipation (FC) | Chronic Idiopathic Constipation (CIC)

United States, United Kingdom, Bulgaria, Netherlands
Astellas Pharma Inc

Completed

A Study to Evaluate the Effect of ASP0456 in Patients With Constipation Predominant Irritable Bowel Syndrome

Constipation-predominant Irritable Bowel Syndrome (IBS-C)

Japan
Zhiguo Liu

Completed

Application of Linaclotide Capsule in Bowel Preparation for Patients at High Risk of Inadequate Bowel Preparation

Colonoscopy

China
Ironwood Pharmaceuticals, Inc.

Completed

Dose-range-finding, Phase 2 Trial of Oral Linaclotide Acetate Administered to Patients With Chronic Constipation

Chronic Constipation

United States
Forest Laboratories
Ironwood Pharmaceuticals, Inc.

Completed

Trial of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation

Irritable Bowel Syndrome Characterized by Constipation

United States, Canada
Changhai Hospital
The First Affiliated Hospital of Nanchang University; The Second Hospital of... and other collaborators

Completed

Application of Linaclotide Capsule in Bowel Preparation for Colonoscopy

Bowel Preparation for Colonoscopy

China
Forest Laboratories

Completed

A Lactation Study in Women Who Are Breastfeeding or Pumping and Are Receiving Linaclotide Therapeutically (LIN-PK-01)

Irritable Bowel Syndrome | Constipation | Breast Feeding

United States
Samjin Pharmaceutical Co., Ltd.

Completed

A Phase 1 Clinical Study to Investigate the Pharmacokinetics and Safety/Tolerability of SA001 in Healthy Male Volunteers

Healthy

Korea, Republic of
Astellas Pharma Inc

Completed

Post-marketing Surveillance of Linaclotide Tablet in Patients With Irritable Bowel Syndrome With Constipation or Chronic Constipation (Excluding Constipation Due to Organic Diseases)

Irritable Bowel Syndrome With Constipation (IBS-C) | Chronic Constipation (CC) (Excluding Constipation Due to Organic Diseases)

Japan
Mayo Clinic
National Cancer Institute (NCI)

Completed

Linaclotide Acetate in Preventing Colorectal Cancer in Healthy Volunteers

Colorectal Cancer | Healthy, no Evidence of Disease

United States
Augusta University
Forest Laboratories

Completed

Investigation of Linaclotide's Effect on the Bi-directional Brain and Gut Axis in IBS-C Patients

Irritable Bowel Syndrome With Constipation (IBS-C)

United States
AstraZeneca
Ironwood Pharmaceuticals, Inc.

Completed

A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Trial of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation (IBS-C) (D5630C00001)

Irritable Bowel Syndrome With Constipation (IBS-C)

United States, Australia, China, New Zealand, Canada
Hospital Ambroise Paré Paris

Completed

Comparison of the Efficacy of rTMS and tDCS of the Motor Cortex in Patients With Chronic Neuropathic Pain

Lumbar Radiculopathy

France
Allergan
Ironwood Pharmaceuticals, Inc.

Completed

Linaclotide Safety and Efficacy in 2 to 5-Year-Old Participants With Functional Constipation

Functional Constipation

United States
Ironwood Pharmaceuticals, Inc.
Forest Laboratories

Completed

Trial of Linaclotide in Patients With Chronic Constipation

Chronic Constipation

United States
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Unknown

Evaluation of Clinical Equivalence Between Two Linaclotide Products in the Treatment of Chronic Idiopathic Constipation

Chronic Idiopathic Constipation

China
Astellas Pharma Inc

Completed

A Study to Evaluate Dose Responses of Efficacy and Safety of ASP0456 in Patient With Chronic Constipation

Chronic Constipation

Japan
E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.

Recruiting

A First-in-Human Study of QY211 Gel in Adult Subjects

Atopic Dermatitis

China
HK inno.N Corporation

Unknown

A Study to Explore Pharmacokinetics/Pharmacodynamics and Safety of Tegoprazan BID Dosing in Healthy Subjects

Healthy

Korea, Republic of
Arthrosi Therapeutics

Completed

Multiple Ascending Dose Study of AR882 in Healthy Adult Male Volunteers

Healthy Volunteers

Australia
Ironwood Pharmaceuticals, Inc.
Allergan Sales, LLC

Completed

A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Irritable Bowel Syndrome Characterized by Constipation

United States
Ironwood Pharmaceuticals, Inc.
Manchester University NHS Foundation Trust

Terminated

A Study of the Effect of Linaclotide on Abdominal Girth in Participants With Irritable Bowel Syndrome With Constipation (IBS-C)

Irritable Bowel Syndrome Characterized by Constipation

United Kingdom
Huabo Biopharm Co., Ltd.

Completed

A Study of HB0017 in Patients With Moderate to Severe Plaque Psoriasis

Plaque Psoriasis

China
Intron Biotechnology, Inc.

Completed

A Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetic/Pharmacodynamic Characteristics of KMRC011

Acute Radiation Syndrome

Korea, Republic of
Pfizer

Terminated

A Single Dose Study Of PF-06291874 In Healthy Adult Subjects

Healthy

United States
Akesobio Australia Pty Ltd

Completed

A Study of AK120 (IL-4Rα) in Healthy Subjects and Subjects With Moderate- to- Severe Atopic Dermatitis

Atopic Dermatitis

New Zealand, Australia
Creabilis SA
LCG Bioscience

Completed

A Study to Assess the Pharmacokinetics, Safety and Tolerability of CT327 in Healthy Male Volunteers

Safety
Ironwood Pharmaceuticals, Inc.
Forest Laboratories

Completed

Trial of Linaclotide in Patients With Chronic Idiopathic Constipation

Chronic Idiopathic Constipation

United States
Ji Xing Pharmaceuticals Australia Pty Ltd
Novotech (Australia) Pty Limited

Recruiting

JX09 SAD/MAD in Healthy Participants

Resistant Hypertension

Australia
AbbVie
Ironwood Pharmaceuticals, Inc.

Recruiting

A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide

Functional Constipation

United States, Bulgaria, United Kingdom, Croatia, Germany, Hungary
aTyr Pharma, Inc.
Foundation for Sarcoidosis Research

Completed

Study of Intravenous ATYR1923 (Efzofitimod) for Pulmonary Sarcoidosis

Pulmonary Sarcoidosis

United States
AceLink Therapeutics, Inc.
Novotech (Australia) Pty Limited

Completed

To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AL01211 in Healthy Volunteers

Autosomal Dominant Polycystic Kidney

Australia
Ironwood Pharmaceuticals, Inc.
Forest Laboratories

Completed

Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Irritable Bowel Syndrome With Constipation

United States
Ali Amini Harandi

Unknown

MLC901 for Moderate to Severe Traumatic Brain Injury (Specified Drug Code) (MLC901)

Traumatic Brain Injury

Iran, Islamic Republic of
Genexine, Inc.

Completed

Safety and Tolerability of GX-P1 in Healthy Male Volunteers

Autoimmune Diseases

Korea, Republic of
Green Cross Corporation
Korean Center for Disease Control and Prevention

Completed

A Study to Assess Dose-Response, Efficacy (Immunogenicity) and the Safety of GC1109 (GC1109)

Anthrax

Korea, Republic of
Janssen Research & Development, LLC

Completed

A Safety and Tolerability Study of 42037788 (Referred to as CNTO 0007) Compared With Placebo in Patients Who Have Experienced Ischemic Cerebral Infarction (Also Known as Stroke)

Infarction | Ischemia | Stroke

United States
Creabilis SA
Aalborg University Hospital

Completed

A Study to Investigate the Pharmacodynamic Effects of CT327 on Intra-dermal Nerve Growth Factor (NGF) and Evoked Pain Responses, in Healthy Male Volunteers

Neuropathic Pain

Denmark

3

Subscribe